Saturday 17 October 2026
Export CSBR’s income statement to Excel — free account
Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.
4.70
0.09
−1.88%
Follow CSBR
Champions Oncology, Inc. (CSBR) P/E ratio
Champions Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,096× (September 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 20.4× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 191× | (53.96%) |
| FY2021 | 414× | — |
| FY2020 | 0.0× | — |
| FY2019 | 908× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Apr 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Oct 2025 | 36.0× | 25.32% |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,096×
Ten-year median
0.0×
Current reading's percentile
75
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CSBR Champions Oncology, Inc. | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)